Abstract
A 51-year old woman with stage III melanoma participated in a phase II clinical trial in which she received subcutaneous rhGM-CSF injections for 3 years. She was in remission by the end of the trial. Seven months after discontinuing GM-CSF she had her first MS event. The unique timeline of rh-GM-CSF injections in a melanoma trial, during which yearly MRI scans showed subtle stable demyelination followed by RRMS onset shortly after discontinuation of treatment, may provide some insight on the role of GM-CSF in MS.
Keywords:
Granulocyte macrophage colony-stimulating factor; Melanoma; Multiple sclerosis.
Published by Elsevier B.V.
Publication types
-
Case Reports
-
Clinical Trial, Phase II
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Brain / diagnostic imaging
-
Female
-
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
-
Granulocyte-Macrophage Colony-Stimulating Factor / adverse effects*
-
Humans
-
Melanoma / drug therapy*
-
Middle Aged
-
Multiple Sclerosis / diagnostic imaging*
-
Multiple Sclerosis / etiology*
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / adverse effects
-
Thigh
Substances
-
Antineoplastic Agents
-
Recombinant Proteins
-
Granulocyte-Macrophage Colony-Stimulating Factor